基因疗法有望被用于改善视力

The trial began with six patients. Two still had excellent visual acuity-clearness of vision-which is measured by reading lines of letters on a sight chart. Two other patients had good acuity and two had reduced acuity.
试验是从六位病人开始的。其中两位病人仍拥有非常高的视敏度，两位病人拥有较高的视敏度，另外两位病人有着较低的视敏度。视敏度也被称为视觉清晰度，通过让病人阅读视力测验表上的字母来衡量。

Six months after the operation, the two patients with reduced acuity showed improved vision, being able to read two and four more lines on the sight chart. The others could see better in dim light. The gains were sustained over several months of follow-up.
术后六个月，两位视敏度较低的病人出现了视觉改善的现象，能够在视力测验表上多看清两到四行字母。其他病人在弱光环境下的视力也得到了增强。这种症状改善在随后的几个月内得以维持。

A 65-year-old in the trial said that when he now watches a soccer game on TV the 'green of the pitch is brighter and the numbers on the shirt much clearer.' Another who went through the procedure says he can now see stars in the night sky, which he hadn't seen for a long time.
接受临床试验的一位65岁患者称，现在当他在电视上观看足球比赛时，绿色的场地更亮眼了，球衣上的号码也更清楚了。另一位接受手术的患者称，他很久都无法看到夜空中的星星，现在他能看到了。

Altering a patient's DNA is risky because it can trigger dangerous side-effects. In this case, there was no sign of an immune reaction in the first six months of the follow-up, according to the Lancet study.
改变患者的DNA是有风险的，因为这可能引来危险的副作用。《柳叶刀》上的研究显示，之后的六个月，患者并未出现有免疫反应的迹象。

The scientists hope to treat patients before their sight falters. 'We want to preserve the vision they've got,' said Prof. MacLaren. He now plans to test the technique on a larger group of about 30 patients.
这些科学家希望在患者彻底失去视力前进行治疗。麦克拉伦教授说，我们希望使患者现有的视力得到维持。他现在计划对约30位患者构成的更大群体测试这项技术。